Quotient Limited  logo

QTNT

Quotient Limited

$0.8

Earnings Summary

Revenue
$6.25Mn
Net Profits
$-27.36Mn
Net Profit Margins
-438%

Highlights

Revenue:

Quotient Limited ’s revenue jumped 5.7% since last year same period to $6.25Mn in the Q3 2018. On a quarterly growth basis, Quotient Limited has generated -20.75% fall in its revenue since last 3-months.

Net Profits:

Quotient Limited ’s net profit fell -26.14% since last year same period to $-27.36Mn in the Q3 2018. On a quarterly growth basis, Quotient Limited has generated -8.68% fall in its net profits since last 3-months.

Net Profit Margins:

Quotient Limited ’s net profit margin fell -19.33% since last year same period to -438% in the Q3 2018. On a quarterly growth basis, Quotient Limited has generated -37.14% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Quotient Limited post its latest quarter earnings

EPS Estimate Current Quarter
-0.16
EPS Estimate Current Year
-0.16

Highlights

EPS Estimate Current Quarter:

Quotient Limited ’s earning per share (EPS) estimates for the current quarter stand at -0.16 - a 20.75% jump from last quarter’s estimates.

EPS Estimate Current Year:

Quotient Limited ’s earning per share (EPS) estimates for the current year stand at -0.16.

Key Ratios

Key ratios of the Quotient Limited post its Q4 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

Quotient Limited ’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q4 2022. This indicates that the Quotient Limited has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-06-28
-0.31
-0.27
14.2%
2023-02-06
-0.16
0
100%
2022-11-14
-0.2
0
100%
2022-08-09
-0.2
-0.37
-83.81%

Company Information

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient's proprietary multiplex microarray technology, offers the world's first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

Organisation
Quotient Limited
Headquarters
Business Park Terre Bonne, Eysins, Switzerland, 1262
Employees
450
Industry
Health Technology
CEO
Franz Walt

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*